RxDoctor Payments Data

Uma Polam, MD

Internal Medicine · Greenbelt, MDNPI 1740241207

Payments from drug & device makers

$1,662in general payments, 2019–2025

Across 87 payments — averaging $19.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$480
  • Amgen$228
  • Pfizer$200
  • Astellas Pharma US Inc$125
  • Sanofi-aventis U.S. LLC$77
  • AbbVie$71
  • plus $481 from 19 others

What the payments were for

  • Food & beverage$1,662100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,662 in reported general payments places this provider in the 75th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$163,811
Medicare patients
290
Services billed
2,046

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin75$102,324
OzempicSemaglutide22$46,441
FarxigaDapagliflozin Propanediol25$29,646
RybelsusSemaglutide11$25,265
LinzessLinaclotide11$6,929
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$4,646
Atorvastatin Calcium259$3,091
Rosuvastatin Calcium100$2,581
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide166$2,336
Albuterol Sulfate HfaAlbuterol Sulfate62$2,217
Nano 2nd Gen Pen NeedlePen Needle, Diabetic17$2,204
Amlodipine Besylate249$1,969
Losartan Potassium164$1,718
Levothyroxine Sodium135$1,686
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide33$1,686

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$26$102,32475 claims
Novo NordiskOzempic, Rybelsus$480$71,70633 claims
AstraZenecaFarxiga$21$29,64625 claims
AbbVieLinzess, Synthroid$71$8,13825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Greenbelt

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →